Stockscreener 앱 받기
15.98
2.86%
-0.47
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia
Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - Defense World
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider
Entrada Therapeutics appoints new President of R&D - Investing.com
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - GlobeNewswire
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - The Bakersfield Californian
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
30 Shares in Mettler-Toledo International Inc. (NYSE:MTD) Acquired by Itau Unibanco Holding S.A. - Defense World
STERIS plc (NYSE:STE) Shares Sold by XTX Topco Ltd - Defense World
Mettler-Toledo International's (NYSE:MTD) investors will be pleased with their decent 100% return over the last five years - Simply Wall St
Mutual of America Capital Management LLC Cuts Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Lavaca Capital LLC Acquires New Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Purchased by Epoch Investment Partners Inc. - Defense World
Seven Eight Capital LP Has $607,000 Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Holdings Lowered by Ensign Peak Advisors Inc - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Shares Up 6.7% - Defense World
GM Advisory Group LLC Takes $214,000 Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Acquired by Beddow Capital Management Inc. - Defense World
Dimensional Fund Advisors LP Cuts Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Bought by Axxcess Wealth Management LLC - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 6.7% - MarketBeat
Tredje AP fonden Trims Stock Position in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Stake Reduced by Meiji Yasuda Asset Management Co Ltd. - Defense World
XTX Topco Ltd Invests $2.49 Million in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Inspire Investing LLC Sells 357 Shares of Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Acquired by Meiji Yasuda Life Insurance Co - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Purchased by Dai ichi Life Insurance Company Ltd - Defense World
Federated Hermes Inc. Has $10.72 Million Holdings in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Business Wire
Quest Partners LLC Has $147,000 Stake in Mettler-Toledo International Inc. (NYSE:MTD) - Defense World
Mettler-Toledo International Inc. (NYSE:MTD) Shares Sold by Commonwealth Equity Services LLC - Defense World
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Yahoo Finance
(TRDA) Technical Data - Stock Traders Daily
Entrada Therapeutics CFO sells shares worth over $47,000 By Investing.com - Investing.com Australia
Entrada Therapeutics CFO sells shares worth over $47,000 - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 Shares - MarketBeat
Entrada Therapeutics CFO sells shares worth over $47,000 - Investing.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - ForexTV.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - Marketscreener.com
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - GlobeNewswire Inc.
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 11.2% - MarketBeat
Oppenheimer Reaffirms "Outperform" Rating for Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics’ (TRDA) “Outperform” Rating Reaffirmed at Oppenheimer - Defense World
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 3% - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates - MSN
Entrada Therapeutics exec sells over $440k in company stock - Investing.com India
Entrada Therapeutics exec sells over $440k in company stock - Investing.com
Entrada Therapeutics exec sells over $440k in company stock By Investing.com - Investing.com UK
California State Teachers Retirement System Lowers Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Sees Strong Trading Volume - MarketBeat
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Expected to Post Q3 2024 Earnings of ($0.47) Per Share - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results - Defense World
William Blair Weighs in on Entrada Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Forecasted to Earn Q3 2024 Earnings of ($0.47) Per Share - Defense World
HC Wainwright Reiterates “Buy” Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.90 EPS - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Shares Gap Up to $14.21 - Defense World
Entrada Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Entrada Therapeutics Inc [TRDA] Investment Appeal on the Rise - Knox Daily
Entrada Therapeutics stock retains buy rating on strong Q2 net income - Investing.com UK
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Shares Gap Up to $14.21 - MarketBeat
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
0.05%
4.86%
자본화:
|
볼륨(24시간):